Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaffeinICU: Oral Caffeine in Critically Ill Adults
NCT05232734Phase 2Suspended
- Sponsor
- Singapore General Hospital
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of caffeine in encephalopathy, sponsored by Singapore General Hospital. Primary endpoint: Duration of mechanical ventilation at 30 days. Started Nov 2022; status: suspended.
02
Drugs
caffeine
03
Conditions
encephalopathy
Beyond the preview
Go deeper on NCT05232734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232734.